Deadline: September 26, 2025
LYVA Labs, in partnership with Innovate UK and leading international experts, has launched the Innovate UK Biomedical Catalyst Accelerator – Future Medicines to support the development of next-generation health and care innovations.
The focus areas are radiopharmaceuticals, microbiome and phage-based therapies, biopharmaceuticals, regenerative and personalised medicines, gene therapies and CAR-T cell therapies, and antimicrobial resistance.
This accelerator is designed to help UK-based SMEs, start-ups, spinouts, and academics at the early stages of SME formation who are developing innovative solutions to address healthcare challenges. Eligible participants should be in early-stage Technology Readiness Levels, typically TRL2-4, with clear commercial routes to market. Organisations working in radiopharmaceuticals innovation are particularly encouraged to apply.
The programme begins with a Pre-Accelerator running from November 2025 to December 2025, offering companies guidance in drug discovery, regulation, market strategy, financing, and investment readiness while helping them build peer networks. Selected participants will then move into the Accelerator stage from January 2026 to March 2026, receiving tailored technical, scientific, and commercial support including investor pitch training, sector introductions, R&D planning, and a comprehensive funding support pack.
Participants will benefit from world-class expertise in drug discovery and regulation, commercial strategy development, market research, funding guidance, pitch preparation, and access to cutting-edge research facilities. Networking opportunities with sector experts, investors, and peer companies will also form a key part of the programme.
Applications must be submitted by 12pm on 26th September 2025.
For more information, visit LYVA Labs.
